Mary Szela Sells 4,358 Shares of TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela sold 4,358 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.13, for a total value of $17,998.54. Following the completion of the sale, the chief executive officer directly owned 768,931 shares in the company, valued at approximately $3,175,685.03. This represents a 0.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock traded up $0.07 during trading on Friday, reaching $3.93. 396,259 shares of the company’s stock were exchanged, compared to its average volume of 269,887. TriSalus Life Sciences, Inc. has a 1-year low of $3.42 and a 1-year high of $7.95. The company has a market cap of $240.95 million, a P/E ratio of -2.15 and a beta of 0.42. The firm’s 50-day moving average price is $4.95 and its 200 day moving average price is $5.30.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. As a group, equities research analysts predict that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TLSI shares. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.00.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC grew its holdings in TriSalus Life Sciences by 1.5% during the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock worth $14,454,000 after acquiring an additional 30,582 shares during the last quarter. AWM Investment Company Inc. bought a new position in shares of TriSalus Life Sciences during the second quarter valued at $6,812,000. Vanguard Group Inc. lifted its holdings in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after purchasing an additional 345,186 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of TriSalus Life Sciences by 32.1% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after purchasing an additional 265,618 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 35.5% in the fourth quarter. Geode Capital Management LLC now owns 751,207 shares of the company’s stock worth $5,245,000 after purchasing an additional 196,752 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Key TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported a slight quarterly earnings beat on March 5 (EPS -$0.12 vs. consensus -$0.13) with revenue roughly in line with expectations — this gives a fundamental rationale for buying interest. MarketBeat TLSI Summary
• Neutral Sentiment: Trading volume was elevated (≈396k shares vs. ~181k average), suggesting the market is actively re-pricing the name; price remains below the 50-day ($4.95) and 200-day ($5.30) moving averages, a neutral-to-cautious technical backdrop.
• Negative Sentiment: CEO Mary T. Szela sold 15,944 shares on March 17 at an average $3.85 (≈$61.4k) and previously sold 4,358 shares on March 11 at $4.13; these transactions reduced her ownership by ~2.07% and ~0.56% respectively — a notable insider reduction. CEO Form 4
• Negative Sentiment: Other officers also reported multiple small sales this week: Richard Marshak (several sales on Mar 11–16). These are modest in dollar terms but collectively add to negative insider-sentiment signals. Marshak Form 4
• Negative Sentiment: Insider sales by Bryan F. Cox (multiple small sales Mar 11–16) and Jodi Devlin (multiple small sales Mar 11–16) were also disclosed, further contributing to the selling narrative. Cox Form 4 Devlin Form 4

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.